CA Patent

CA2757019C — Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide

Assigned to Colucid Pharmaceuticals Inc · Expires 2018-05-15 · 8y expired

What this patent protects

The present invention re-lates to discloses a pharmaceutical com-position of 2,4,6- trifluoro-N-[6-(1--methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide and a pharma-ceutically acceptable carrier.

USPTO Abstract

The present invention re-lates to discloses a pharmaceutical com-position of 2,4,6- trifluoro-N-[6-(1--methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide and a pharma-ceutically acceptable carrier.

Drugs covered by this patent

Patent Metadata

Patent number
CA2757019C
Jurisdiction
CA
Classification
—
Expires
2018-05-15
Drug substance claim
No
Drug product claim
No
Assignee
Colucid Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.